The company faces imminent liquidity pressure and will likely need to raise capital in the near term, which would be highly dilutive given the $4M market cap. Traders should watch for any financing announcements, partnership deals, or strategic alternatives. The stock may also be at risk of delisting if it cannot meet Nasdaq continued listing standards.
Price Chart
Executive Summary
Indaptus Therapeutics reported Q1 2026 net loss of $2.5M ($0.23 loss per share) and ended the period with only $1.5M in cash, down from $8.5M at year-end 2025. Operating cash burn was $7.0M in the quarter, and the company explicitly states it will need additional capital to continue operations, with no assurance of financing. Combined with a management transition and a pause in clinical trial enrollment, the filing signals a severe near-term funding risk for this pre-revenue biotech.
Key Financial Metrics
Key Facts
- Cash and cash equivalents fell from $8.5M (Dec 31, 2025) to $1.5M (Mar 31, 2026), a decline of $7.0M in one quarter.
- Net cash used in operating activities was $7.0M for Q1 2026, compared to $5.0M in Q1 2025.
- No financing activity occurred in Q1 2026, versus $3.2M raised in Q1 2025.
- Net loss improved to $2.5M from $4.5M year-over-year, but loss per share fell from $9.11 to $0.23 due to a massive increase in weighted-average shares outstanding (10.96M vs 0.50M).
- The company states it will need to raise additional capital and there can be no assurance such financing will be available.
- Executive management transition (new CEO Junyi Dai) and a reassessment of development priorities are underway.
- All outstanding Series AA and AAA preferred stock converted into common stock during Q1 2026.
- The company paused enrollment in its Phase 1 combination study pending further evaluation.
Financial Impact
Cash burn of $7.0M in Q1 2026 left only $1.5M, implying less than one quarter of runway without additional funding.
Risk Factors
- Going concern risk if additional financing is not secured within months.
- Severe dilution from any equity or convertible financing.
- Potential Nasdaq delisting if market cap or bid price falls below thresholds.
- Clinical pipeline uncertainty: the Phase 1 trial is paused and development priorities are being reassessed.
- Management transition adds execution risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-023344 |
| Document: form8-k.htm | 0001493152-26-023344 |
| Document: 0001493152-26-023344-index-headers.html | 0001493152-26-023344 |
| Document: 0001493152-26-023344-index.html | 0001493152-26-023344 |
| Document: 0001493152-26-023344.txt | 0001493152-26-023344 |
| 8-K Data (Synthetic) | 0001493152-26-023344 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $2.56 $3.93 | ▼ −53.52% | ▼ −52.89% | $2.38 (+7.03%) |
Sep 4, 2026 28d ago | 424B5 | $1.85 $3.64 | ▼ −96.76% | ▼ −97.88% | $2.38 (−28.65%) |
Sep 1, 2026 4w ago | 8-K | $1.13 $2.08 | ▼ −84.07% | ▼ −83.99% | $2.38 (−110.62%) |
Aug 26, 2026 5w ago | EFFECT | $1.14 $1.17 | ▼ −2.63% | ▼ −2.75% | $2.38 (−108.77%) |
Aug 17, 2026 6w ago | S-3 | $0.9361 $1.10 | ▼ −16.97% | ▼ −17.18% | $2.38 (−154.25%) |
Aug 13, 2026 7w ago | 8-K | $1.06 $1.38 | ▲ +30.19% | ▲ +32.15% | $2.38 (+124.53%) |
Jul 20, 2026 10w ago | EFFECT | $2.46 $2.61 | ▼ −6.10% | ▼ −6.52% | $2.38 (+3.25%) |
Jun 26, 2026 13w ago | S-3 | $3.06 $2.85 | ▲ +6.86% | ▲ +8.25% | $2.38 (+22.22%) |
Jun 24, 2026 14w ago | 8-K | $3.26 $2.94 | ▲ +9.82% | ▲ +11.38% | $2.38 (+26.99%) |
May 15, 2026 20w ago | 8-K | $1.59 $1.22 | ▲ +23.27% | ▲ +24.23% | $2.38 (−49.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access